There has been controversy around aducanumab, which targets the cause rather than the symptoms.
admin, , TOP STORIES, 0
Related Articles
Stress test
Being one of those few women was not easy. In the 1960s and ’70s, when she continued at MIT...
The Download: testing wastewater for measles, and the cost of nature
Measles is back with a vengeance. In the UK, where only 85% of school-age children have received two doses...
Roundtables: Trump’s Impact on the Next Generation of Innovators
Every year, MIT Technology Review recognizes dozens of young researchers on our Innovators Under 35 list. We checked back...
CIA’s new tech recruiting pitch: More patents, more profits
America’s most famous spy agency has a major competitor it can’t quite seem to beat: Silicon Valley. The CIA...
Podcast: How pricing algorithms learn to collude
Algorithms now determine how much things cost. It’s called dynamic pricing and it adjusts according to current market conditions...
